09996 PEIJIA-B
- 3.860
- -0.070-1.78%
PEIJIA-B News
PUYIN INTERNATIONAL: Maintains a "buy" rating on PEGA MEDICAL-B (09996) with a target price of 7.5 Hong Kong dollars.
Peijia Healthcare (9996.HK): The company's value is undervalued by the market, and “exit” is the biggest factor suppressing stock prices in the short term
Peijia Medical-B (09996.HK): 1H24 loss reduction exceeds expectations and expectations are gradually realized in profit
PEIJIA MEDICAL(9996.HK):SIGNIFICANT LOST REDUCTION ON IMPROVED OPERATING EFFICIENCY
PEIJIA MEDICAL(9996.HK):UNEXCITING TAVR REVENUE IN 1H24
Peijia Healthcare (9996.HK): Audit results may inject more confidence into investors, and major new products are expected to become stock price catalysts
Peijia Medical-B (9996.HK): Dual-wheel drive performance of valvular intervention and neurological intervention continues to grow at a high level
Peijia Medical-B (9996.HK): Valve and Shinsuke Two-wheel Drive Innovation Empowers Growth
Peijia Medical-B (09996.HK): Major R&D progress in the first half of the year was in line with expectations
Peijia Medical-B (09996.HK): 23H1 performance is impressive, valves/nerve pipelines continue to gain strength
Peijia Medical-B (9996.HK): TAVR/Neural Intervention Dual Wheel Drive Operation Efficiency Optimization
Peijia Medical-B (9996.HK): TAVR Braves New Advanced Neurological Interventions Flourish
Peijia Medical-B (09996.HK): Outstanding 23H1 operating data and rapid revenue growth
Peijia Medical-B (09996.HK): TAVR's market share continues to expand and accelerate sales of Shensuke products
Peijia Medical-B (9996.HK): TAVR innovates new advanced neurological intervention products
Peijia Healthcare (9996.HK): Interventional Device Incubation Platform Unveiled on 2023 R&D Day to Show Depth of Pipeline Layout
Peijia Medical-B (09996.HK): Research pipeline progressed smoothly, TAVR implants recovered strongly
Peijia Healthcare (9996.HK): Adjust 2022-24E profit forecast and maintain target prices
Peijia Medical-B (9996.HK): Revenue continues to grow rapidly under the influence of the epidemic and is optimistic about the company's long-term development
Peijia Medical-B (09996.HK): The performance forecast is basically in line with expectations for accelerated growth in 2023
No Data
